• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: U.S. needs national registry for study volunteers

Report: U.S. needs national registry for study volunteers

March 17, 2011
CenterWatch Staff

The U.S. should consider establishing a national registry for healthy volunteers participating in phase I clinical trials to guard against the risks of overlapping enrollment and protect data integrity, Pharma Times reports from a commentary in the Journal of the American Medical Association.

David Resnik of the U.S. National Institute of Environmental Health Sciences and Greg Koski of the James Mongan Institute for Health Policy wrote that some people in the U.S. have enrolled in as many as 80 phase I studies, to the extent of pursuing research participation as a full-time job.

This intense commitment heightens the risk of potentially dangerous drug interactions between investigational agents and medication taken by the study participant either currently or recently, Resnik and Koski wrote. The risk is especially pronounced in phase I trials “designed to induce toxicity to determine the maximum tolerable dose.”

While there is a standard exclusion interval of 30 days for phase I trials in the U.S., and protocols should ideally specify an appropriate waiting period based on the half-life of the investigational drug, professional volunteers “have a strong financial incentive to conceal recent or even current enrollment in phase I studies,” they wrote.

A number of countries, such as France and the U.K., already have national registries for healthy volunteers participating in clinical research, Resnik and Koski pointed out.

“To adequately deal with the problem of overlapping enrollment, a national registry is needed,” Resnik and Koski argued. This should be linked to databases providing investigators with key information about studies the volunteers have participated in, such as interventions, drugs taken, estimated duration of research and contact information. Costs “would be modest and could be financed by fees from study sponsors.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing